Figure 4. Svg3 elicited potent IFN-I responses in human monocytes and ex vivo human tumor tissues.

A) Svg3 elicited potent IFN-I responses that outperformed STING agonist 2’3’-cGAMP in human THP-I monocytes. Marked on the right of treatment legends are EC50. Svg3 and 2’3’-cGAMP were transfected using lipofectamine 2000. B) Relative gene expression showed that Svg3 elicited IFN-I responses in ex vivo HNSCC tissues. Liposomal Svg3 (Svg3: 100 nM) were injected directly into cultured tumor tissues (cohort study, n = 3) cultured in medium (1 mL). 24 h later, the mRNA levels of related cytokines were determined by qPCR. Data: mean ± S.D. P values were determined by t-test (ns: not significant, p > 0.05; *p < 0.05.).